The global Lung Cancer Surgery Market was valued at US$ 1.23 Billion in 2021 and is expected to reach US$ 1.98 Billion by 2029, finds Future Market Insights (FMI) in a recent market survey.
| Data Points | Market Insights |
|---|---|
| Market Value 2021 | USD 1.23 Billion |
| Market Value 2022 | USD 1.31 Billion |
| Market Value 2029 | USD 1.98 Billion |
| CAGR 2022 to 2029 | 6.1% |
| Share of Top 5 Countries | 61.5% |
| Key Players | The key players in the lung cancer surgery market are Asap Endoscopic Products; Ethicon Inc. (J & J); Medtronic Plc.; Germed USA Inc.; Teleflex Incorporated; B. Braun Melsungen AG; Karl Storz; Richard Wolf; Olympus Medical Systems Corp; Intuitive Surgical Inc.; Ambu A/S; PENTAX Medical Company and FUJIFILM Holdings Corporation |
Lung cancer refers to the growth of abnormal cells in the lung tissue. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major types of lung cancer. Treatment options for lung cancer usually include various types of therapies such as chemotherapy, radiation therapy, immunotherapy, targeted drug therapy and surgery.
Attempts to cure the disease with surgery involve the removal of the tumour, the surrounding lung tissue, and lymph nodes in the tumour area. Surgery is considered the treatment of choice for localized cancer, including carcinoid tumours.
The rising level of air pollution in developing economies and the increasing research and development activities on cancer treatment are some of the major trends bolstering the market outlook. The National Cancer Institute, for example, has been significantly offering funds to promote new cancer treatments and improve patient care, which in turn, could boost the acceptance of lung cancer removal surgery globally.
The lung cancer surgery market holds nearly 10% of the US$ 12 Billion cancer surgery market in 2021. Additionally, substantial investment in research laboratories, the surge in air pollution levels, and increasing smoking habits coupled with favourable reimbursement policies, specifically in developed countries will strengthen the growth of the lung cancer surgery market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 6.15% |
| H1, 2022 Projected | 6.12% |
| H1, 2022 Outlook | 6.02% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 12 ↓ |
The growth rates and development prospects of the global lung cancer surgery market are reviewed by FMI. The market is influenced by the development of robotic surgery techniques as well as innovative systemic treatments as a result of the impact of macro and industrial determinants. Growing lobectomy adoption among patients of all ages, as well as rising surgical treatment affordability, are all vital market prospects.
The market growth rate of lung cancer surgery will witness a drop by 12 Basis Point Share (BPS) in H1-2022, according to FMI. However the difference in BPS value between H1- 2022 Outlook and H1-2022 Projected showed a decline in BPS value by 10 BPS. Owing to the morbid effects of detectable lung cancer, the importance of surgical resection procedures was well established with the advent of the COVID-19 pandemic.
The reduced volumes of surgical procedures globally, imposed a restrictive impact on the overall lung cancer surgery market, with relevance to concerns regarding the proliferation of infectious agents.
Two positives for the industry are the rise of minimally invasive techniques, sublobar resection and LND indication for early-stage NSCLC, and targeted therapy and immunotherapy combination with lung cancer surgery for advanced-stage and metastatic lung malignancies. Ongoing research and development in this field show promising growth within this market in the future.
Rising air pollution and the people getting affected by it are one of the prime factors responsible for the growth of the lung cancer surgery market. As per the lung cancer research foundation, lung cancer is the main reason for cancer death across the world.
According to the American Cancer Society, it is estimated that in 2022, around 236,740 adults in the USA will be diagnosed with lung cancer while there will be 130,180 cases of deaths due to lung cancer in the same year. Smoking is the prominent risk factor for lung cancer and is responsible for 80% of lung cancer deaths. Non-smokers account for 20% of lung cancer deaths.
Exposure to radon gas is another risk factor for lung cancer. This indicates the burden of lung cancer in the region and this is resulting in the growth of the lung cancer surgery market as there is a high demand for cancer treatment in the USA
The demand for lung cancer surgery grew at a CAGR of 5.5% between 2014 and 2021 globally. The rise in cases of lung cancer expects to raise the demand for lung cancer surgery.
Growing incidences of lung cancer are expected to favor the demand for lung cancer surgery devices, owing to the large patient pool and need for effective treatment. Lung cancer incidences are increasing rapidly with the increase in the high smoking rates, environmental pollution, and workplace exposures in milling, construction, and automobile repairs.
Similarly, cigarette smoking is also one of the most common and known factors for developing lung cancer. Men who smoke often have 23 times more chances to develop lung cancer compared to non-smokers. Non-smokers have 20 to 30% chances of developing lung cancer due to exposure to secondhand smoke at work and at home.
The lung cancer surgery market is expected to grow in the future, as the emergence of the latest technologies in the medical sector and the introduction of technologically advanced surgical energy instruments are magnifying the demand for this market. Advanced endoscopic devices and surgical instruments have increased the device versatility, thus easing their use of it in complex cases, leading to an increase in the number of lung resection procedures. Technology transformation has led to a positive impact on the global lung cancer surgery market growth.
Considering this, FMI expects global lung cancer surgery to grow at a CAGR of 6.1% through 2029.
Principal Consultant
Lung cancer surgeries such as lobectomy, wedge resection, and other procedures are very high-cost surgeries. Affordability of the endoscopy and video-assisted lung surgery procedures is a major problem for a huge chunk of the population in the region. This is due to the absence of health insurance and limited government support policies that cover video-assisted surgeries in developing countries such as South Africa, India, and China.
The absence of social health insurance together with the exclusionary provision of private health insurance schemes is another major factor limiting the lung cancer surgery market growth. Furthermore, post-surgery infections and risks associated with lung surgery are also expected to hamper the growth of the lung cancer surgery market.
Lung resection procedures are often associated with various post-surgery complications and infections in some patients. Air leak is the most common complication after the lung resection procedure. Around 15% to 20% of patients reported air leaks after lung resection surgery. Some of the other complications associated with lung resection surgery include bacterial pneumonia, acute respiratory failure, pulmonary embolism, postoperative haemorrhage, comorbid cardiovascular conditions, and other conditions. All these factors might result in restraining the demand for these procedures during the forecast period.
In 2021, the USA is expected to account for about 93.9% of the North American lung cancer surgery market due to ease in FDA clearance encouraging lung cancer surgery device manufacturers in the region. For endoscope medical devices, the FDA 510(k) premarket approval process is followed. The Food and Drug Administration (FDA) has provided a list of class II (special control) devices that were subjected to certain limitations and which are now exempted from premarket notification requirements as per the Food and Drug Administration Modernization Act of 1997 (known as Modernization Act).
As per the Modernization Act and the related exemptions, device manufacturers and developers are relieved from the need to submit premarket submissions. Thus, enabling FDA to redirect resources to more significant public health issues. This helps minimize the time taken for regulatory approvals. Thus, reducing costs significantly and propelling the growth of the thoracoscope, and bronchoscope markets as well as boosting the growth of the lung cancer surgery devices market in the USA
Germany is expected to account for 24.2% of the European market by 2021. The country dominates the European market owing to the high prevalence of lung cancer in Germany.
As per World Health Organization and Globocan, a total of 64,804 individuals were identified to have lung cancer in Germany which is nearly 10% of the total 628,519 cancer cases in 2020. Lung cancer was ranked 3rd on basis of its incidence rates while it was considered the top reason behind the deaths caused by cancer.
The market for lung cancer surgery in China is projected to grow at 7.8% CAGR in the East Asia region throughout the forecast period. The high prevalence of lung cancer among the older population led to increased demand for lung cancer surgeries in China.
The rapid rise in China’s adult population suffering from lung cancer is anticipated to boost the growth of the country’s lung cancer surgery market. This is because the maximum number of people diagnosed with lung cancer are 65 years and older. A small number of people aged below 45 are diagnosed with lung cancer. According to the WHO, by 2040, the elder population is expected to grow by 28% in China.
As per Globocan, Lung cancer was ranked 1st when considering the number of new cases (incidence rate) and highest no of deaths (mortality rate) due to different types of cancer. Around 815,563 new cases of lung cancer were identified in 2020 in China, whereas 714,699 cases of deaths were reported due to the same.
Demand for lung cancer surgery in India is expected to rise at an impressive 6.8% CAGR over the forecast period. Asian countries have the highest population suffering from Chronic obstructive pulmonary disease (COPD), thus the risk of developing lung cancer increases significantly in the region. The number of COPD cases in India was a shocking 55.3 million in 2016.
The threat of lung cancer in patients with COPD is two- to fivefold more compared with smokers without COPD. COPD prevalence is rising at a very high rate which is expected to increase the risk of lung cancer and favor the growth of the lung cancer surgery market over the forecast period in India. Moreover, as per the report published by WHO, levels of ultra-fine particles of less than 2.5 microns are the maximum in India, which led India to become the 16th most polluted city in the world, among the 30 most polluted cities. Thus, a rise in air pollution is primarily driving the lung cancer rate, and hence the Indian market is expected to be impacted.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Based on the product type, the surgical energy instruments segment holds the maximum share of 42.5% in 2021, expanding at 6.6% CAGR during the forecast period. Advanced surgical instruments have increased the device adaptability and ease of use in complex surgical procedures, which drives lung cancer surgical procedures. Furthermore, Technology transformation has supplemented the growth of the surgical energy instruments segment.
In terms of Application, the lobectomy segment accounted for 68.0% of the total market share in 2021. Growing acceptance of VATS lobectomy is expected to favor the demand for endoscopic surgery equipment and advanced energy equipment and drive the growth of the lobectomy segment.
By End Users, Hospitals hold over 78.8% of the market in 2021 and this trend is expected to continue during the forecast period as well.
Market players lay greater emphasis on collaboration and partnership activities with local and regional players to expand sales and after-sales services for lung cancer surgery devices.
Through partnerships and acquisitions with regional players and third-party service vendors, manufacturers expand their presence and product availability on a global level which is anticipated to fuel the growth of the lung cancer surgery devices market. For instance:
| Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historical Data Available for | 2014 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Poland, Russia, France, United Kingdom, Germany, Spain, Italy, Benelux, Nordic, China, India, Australia and New Zealand, ASEAN, GCC Countries, Turkey, North Africa, and South Africa |
| Key Segments Covered | Product Type, Application, End-User, and Region |
| Key Companies Profiled | Asap Endoscopic Products; Ethicon Inc. (J & J); Medtronic Plc.; Germed USA Inc.; Teleflex Incorporated; B. Braun Melsungen AG; Karl Storz; Richard Wolf; Olympus Medical Systems Corp; Intuitive Surgical Inc.; Ambu A/S; PENTAX Medical Company; FUJIFILM Holdings Corporation |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global lung cancer surgery market is worth US$ 1.23 Billion in 2021 and is set to expand 1.5X over the next seven years.
The lung cancer surgery market is expected to reach US$ 1.98 Billion by the end of 2029, with sales revenue expected to grow at a 6.1% CAGR.
The global market for lung cancer surgery is projected to reflect high demand in the forecast period with a CAGR of 6.1% owing to the rising prevalence of COPD and increased risk of lung cancer.
North America currently holds the largest market share in the lung cancer surgery market globally. North America currently holds 36.5% of the global market share in the lung cancer surgery market with the USA being the leading contributor with a market value of over US$ 421.5 Million in 2021.
The lung cancer surgery market in India is likely to grow at a CAGR of 6.8% during the forecast period, with a market share of around 48.8% in 2021 of the South Asia market for lung cancer surgery. The rising prevalence of COPD and lung cancer in India, and growing awareness among the population are responsible for the growth of the lung cancer surgery market in India.
The growing focus on the introduction of new robotic surgery systems and the increasing launch of new endovascular technology for tissue-specific vessel sealing and stapling techniques are the major key trends in the lung cancer surgery market.
Japan’s market in lung cancer surgery is offering lucrative growth opportunities and is expected to exhibit healthy growth of 6.3% CAGR during the forecast period.
The USA, China, Germany, Japan, and the United Kingdom are the top 5 countries that are driving the demand for lung cancer surgery.
Leading companies in lung cancer surgery are Asap Endoscopic Products, Ethicon Inc. (J & J), Medtronic Plc., Germed USA Inc., Teleflex Incorporated, B. Braun Melsungen AG, Karl Storz, Richard Wolf, Olympus Medical Systems Corp, Intuitive Surgical Inc., Ambu A/S, PENTAX Medical Company, and FUJIFILM Holdings Corporation.
1. Executive Summary | Lung Cancer Surgery Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Key Product USP Analysis 4.2. Regulatory Scenario 4.3. Reimbursement Scenario 4.4. Value Chain 4.5. Disease Epidemiology by Region 5. Global Market Demand (in Value or Size in US$ Million) Analysis 2014 to 2021and Forecast, 2022 to 2029 5.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021 5.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2029 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Global Healthcare Market Outlook 6.2. Forecast Factors - Relevance & Impact 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity Analysis 7. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Product Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Product Type, 2014 to 2021 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2029 7.3.1. Thoracoscopes 7.3.2. Mediastinoscopes 7.3.3. Bronchoscopes 7.3.4. Robotic-Assisted Thoracic Surgery Systems 7.3.5. Surgical Staplers 7.3.6. Surgical Energy Instruments 7.3.6.1. Advanced Energy Instruments 7.3.6.1.1. Advanced Bipolar Instruments 7.3.6.1.2. Ultrasonic Instruments 7.3.6.2. Basic Energy Instruments 7.3.6.2.1. Bipolar Instruments 7.3.6.2.2. Monopolar Instruments 7.4. Market Attractiveness Analysis By Product Type 8. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Application 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Application, 2014 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2029 8.3.1. Lobectomy 8.3.2. Segmentectomy 8.3.3. Wedge Resection 8.3.4. Pneumonectomy 8.4. Market Attractiveness Analysis By Application 9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By End User, 2014 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2029 9.3.1. Hospitals 9.3.2. Ambulatory Surgical Centers 9.4. Market Attractiveness Analysis By End User 10. Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By End User, 2014 to 2021 10.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2029 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Middle East and Africa (MEA) 10.3.5. East Asia 10.3.6. South Asia 10.3.7. Oceania 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 11.1. Introduction 11.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021 11.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029 11.3.1. By Country 11.3.1.1. USA 11.3.1.2. Canada 11.3.2. By Product Type 11.3.3. By Application 11.3.4. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Product Type 11.4.3. By Application 11.4.4. By End User 12. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021 12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Rest of Latin America 12.3.2. By Product Type 12.3.3. By Application 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product Type 12.4.3. By Application 12.4.4. By End User 13. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Trend Analysis By Market Taxonomy, 2014 to 2021 13.3. Market Size (US$ Million) and By Market Taxonomy, 2022 to 2029 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. United Kingdom 13.3.1.5. Spain 13.3.1.6. Russia 13.3.1.7. Rest of Europe 13.3.2. By Product Type 13.3.3. By Application 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product Type 13.4.3. By Application 13.4.4. By End User 14. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Trend Analysis By Market Taxonomy, 2014 to 2021 14.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Thailand 14.3.1.3. Indonesia 14.3.1.4. Malaysia 14.3.1.5. Rest of South Asia 14.3.2. By Product Type 14.3.3. By Application 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product Type 14.4.3. By Application 14.4.4. By End User 15. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Trend Analysis By Market Taxonomy, 2014 to 2021 15.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Product Type 15.3.3. By Application 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product Type 15.4.3. By Application 15.4.4. By End User 16. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Trend Analysis By Market Taxonomy, 2014 to 2021 16.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Product Type 16.3.3. By Application 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product Type 16.4.3. By Application 16.4.4. By End User 17. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Trend Analysis By Market Taxonomy, 2014 to 2021 17.3. Market Size (US$ Million) and Forecast By Market Taxonomy, 2022 to 2029 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Turkey 17.3.1.3. Northern Africa 17.3.1.4. South Africa 17.3.1.5. Rest of Middle East and Africa 17.3.2. By Product Type 17.3.3. By Application 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product Type 17.4.3. By Application 17.4.4. By End User 18. Emerging Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. China Market Analysis 18.2.1. Introduction 18.2.2. Market Value Proportion Analysis by Market Taxonomy 18.2.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy 18.2.3.1. By Product Type 18.2.3.2. By Application 18.2.3.3. By End User 18.2.4. China Market - Competition Landscape 18.3. India Market Analysis 18.3.1. Introduction 18.3.2. Market Value Proportion Analysis by Market Taxonomy 18.3.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy 18.3.3.1. By Product Type 18.3.3.2. By Application 18.3.3.3. By End User 18.3.4. India Market - Competition Landscape 18.4. Brazil Market Analysis 18.4.1. Introduction 18.4.2. Market Value Proportion Analysis by Market Taxonomy 18.4.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy 18.4.3.1. By Product Type 18.4.3.2. By Application 18.4.3.3. By End User 18.4.4. Brazil Market - Competition Landscape 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Deep Dive 20.2.1. Asap Endoscopic Products 20.2.1.1. Overview 20.2.1.2. Product Portfolio 20.2.1.3. Profitability by Market Segments (Product/Channel/Region) 20.2.1.4. Sales Footprint 20.2.1.5. Strategy Overview 20.2.2. Ethicon Inc. (J & J) 20.2.2.1. Overview 20.2.2.2. Product Portfolio 20.2.2.3. Profitability by Market Segments (Product/Channel/Region) 20.2.2.4. Sales Footprint 20.2.2.5. Strategy Overview 20.2.3. Medtronic Plc. 20.2.3.1. Overview 20.2.3.2. Product Portfolio 20.2.3.3. Profitability by Market Segments (Product/Channel/Region) 20.2.3.4. Sales Footprint 20.2.3.5. Strategy Overview 20.2.4. Germed USA Inc. 20.2.4.1. Overview 20.2.4.2. Product Portfolio 20.2.4.3. Profitability by Market Segments (Product/Channel/Region) 20.2.4.4. Sales Footprint 20.2.4.5. Strategy Overview 20.2.5. Teleflex Incorporated 20.2.5.1. Overview 20.2.5.2. Product Portfolio 20.2.5.3. Profitability by Market Segments (Product/Channel/Region) 20.2.5.4. Sales Footprint 20.2.5.5. Strategy Overview 20.2.6. B. Braun Melsungen AG 20.2.6.1. Overview 20.2.6.2. Product Portfolio 20.2.6.3. Profitability by Market Segments (Product/Channel/Region) 20.2.6.4. Sales Footprint 20.2.6.5. Strategy Overview 20.2.7. Karl Storz 20.2.7.1. Overview 20.2.7.2. Product Portfolio 20.2.7.3. Profitability by Market Segments (Product/Channel/Region) 20.2.7.4. Sales Footprint 20.2.7.5. Strategy Overview 20.2.8. Richard Wolf 20.2.8.1. Overview 20.2.8.2. Product Portfolio 20.2.8.3. Profitability by Market Segments (Product/Channel/Region) 20.2.8.4. Sales Footprint 20.2.8.5. Strategy Overview 20.2.9. Olympus Medical Systems Corp 20.2.9.1. Overview 20.2.9.2. Product Portfolio 20.2.9.3. Profitability by Market Segments (Product/Channel/Region) 20.2.9.4. Sales Footprint 20.2.9.5. Strategy Overview 20.2.10. Intuitive Surgical Inc. 20.2.10.1. Overview 20.2.10.2. Product Portfolio 20.2.10.3. Profitability by Market Segments (Product/Channel/Region) 20.2.10.4. Sales Footprint 20.2.10.5. Strategy Overview 20.2.11. Ambu A/S 20.2.11.1. Overview 20.2.11.2. Product Portfolio 20.2.11.3. Profitability by Market Segments (Product/Channel/Region) 20.2.11.4. Sales Footprint 20.2.11.5. Strategy Overview 20.2.12. PENTAX Medical Company 20.2.12.1. Overview 20.2.12.2. Product Portfolio 20.2.12.3. Profitability by Market Segments (Product/Channel/Region) 20.2.12.4. Sales Footprint 20.2.12.5. Strategy Overview 20.2.13. FUJIFILM Holdings Corporation 20.2.13.1. Overview 20.2.13.2. Product Portfolio 20.2.13.3. Profitability by Market Segments (Product/Channel/Region) 20.2.13.4. Sales Footprint 20.2.13.5. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Lung Cancer Surgery Market
